
UroGen Pharma (URGN) Stock Forecast & Price Target
UroGen Pharma (URGN) Analyst Ratings
Bulls say
UroGen Pharma Ltd has demonstrated significant financial growth, with full-year net product revenue increasing by 9% to $90.4 million in 2024, attributed to the rising demand for its flagship product, JELMYTO, which saw a 15% year-over-year increase in Q4 revenue. The company's projections indicate robust future sales, anticipating $114.1 million in 2025 and escalating to $338.8 million in 2026, bolstered by the promising outcomes of investigational candidate UGN-102, which has shown an 18-month duration of response of 80.6% in clinical trials. Furthermore, UroGen's strategic positioning in a market opportunity exceeding $5 billion, particularly with the potential commercial launch of UGN-102, supports a positive outlook on the company's long-term growth trajectory.
Bears say
UroGen Pharma Ltd reported a full-year 2024 net loss of $2.96 per share, with a notable widening of its Q4 net loss to $37.5 million compared to $26.0 million in the prior-year period, reflecting growing financial challenges. Key risks impacting the company's outlook include heightened competition reducing market penetration, potential clinical failures of investigative candidates, and difficulties in extending market exclusivity for core franchises. Furthermore, the company experienced a modest revenue miss in Q4 2024 with $24.6 million in top-line revenue, prompting adjustments to long-term revenue ramp expectations and necessitating reductions in financial forecasts.
This aggregate rating is based on analysts' research of UroGen Pharma and is not a guaranteed prediction by Public.com or investment advice.
UroGen Pharma (URGN) Analyst Forecast & Price Prediction
Start investing in UroGen Pharma (URGN)
Order type
Buy in
Order amount
Est. shares
0 shares